• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

作者信息

Nijenhuis C M, Huitema A D R, Blank C, Haanen J B A G, van Thienen J V, Rosing H, Schellens J H M, Beijnen J H

机构信息

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.

Division of Immunology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

出版信息

J Clin Pharmacol. 2017 Jan;57(1):125-128. doi: 10.1002/jcph.788. Epub 2016 Jul 29.

DOI:10.1002/jcph.788
PMID:27365214
Abstract
摘要

相似文献

1
Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.维莫非尼在BRAF基因变异型黑色素瘤患者中的临床药代动力学
J Clin Pharmacol. 2017 Jan;57(1):125-128. doi: 10.1002/jcph.788. Epub 2016 Jul 29.
2
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.血浆维莫非尼暴露量和治疗前肝细胞生长因子水平是导致BRAF突变型黑色素瘤患者早期外周淋巴细胞耗竭的两个因素。
Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1.
3
Vemurafenib therapy for stage IV melanoma with V600G-mutation.维莫非尼治疗伴有V600G突变的IV期黑色素瘤
J Dtsch Dermatol Ges. 2013 Dec;11(12):1198-9. doi: 10.1111/ddg.12200. Epub 2013 Sep 9.
4
BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.BRAF（V600）突变水平可预测转移性黑色素瘤对维莫非尼的反应。
Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088.
5
Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.以罕见的BRAF突变且对维莫非尼无反应为特征的快速转移恶性黑色素瘤。
J Dtsch Dermatol Ges. 2014 Feb;12(2):151-4. doi: 10.1111/ddg.12231. Epub 2013 Nov 18.
6
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.维莫非尼治疗 BRAF(V600) 突变转移性黑色素瘤患者：一项开放性、多中心、安全性研究。
Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.
7
[Treatment of metastatic melanoma with BRAF inhibitors].用BRAF抑制剂治疗转移性黑色素瘤
Hautarzt. 2011 Sep;62(9):696-8. doi: 10.1007/s00105-011-2232-8.
8
Safety of vemurafenib in patients with BRAF mutated metastatic melanoma: the Spanish experience.维莫非尼在BRAF突变转移性黑色素瘤患者中的安全性：西班牙的经验。
Clin Transl Oncol. 2016 Nov;18(11):1147-1157. doi: 10.1007/s12094-016-1498-9. Epub 2016 Mar 17.
9
Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.采用维莫非尼诱导治疗，随后对无法手术治愈的黑色素瘤进行巩固性放射治疗。
Melanoma Res. 2015 Jun;25(3):246-51. doi: 10.1097/CMR.0000000000000154.
10
Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.维莫非尼在晚期BRAF突变黑色素瘤门诊患者中的药代动力学及其与疗效和安全性的相关性。
Target Oncol. 2016 Feb;11(1):59-69. doi: 10.1007/s11523-015-0375-8.

引用本文的文献

1
Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots.建立并验证了一种从干血斑中定量检测卡博替拉韦和利匹韦林的液相色谱-串联质谱分析方法。
J Pharm Biomed Anal. 2023 May 10;228:115307. doi: 10.1016/j.jpba.2023.115307. Epub 2023 Feb 17.
2
Targeting the "undruggable" RAS - new strategies - new hope?靶向“不可成药”的RAS——新策略——新希望？
Cancer Drug Resist. 2019 Sep 19;2(3):813-826. doi: 10.20517/cdr.2019.21. eCollection 2019.
3
Therapeutic drug monitoring of oral targeted antineoplastic drugs.
口服靶向抗肿瘤药物的治疗药物监测。
Eur J Clin Pharmacol. 2021 Apr;77(4):441-464. doi: 10.1007/s00228-020-03014-8. Epub 2020 Nov 9.
4
Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.在精准医学时代，肿瘤学中口服靶向治疗的个体化剂量至关重要。
Eur J Clin Pharmacol. 2019 Sep;75(9):1309-1318. doi: 10.1007/s00228-019-02704-2. Epub 2019 Jun 7.
5
The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study.剂量和抑酸剂同时使用对转移性 BRAF V600 突变型黑色素瘤中维莫非尼疗效的影响：一项回顾性队列研究。
Target Oncol. 2018 Jun;13(3):363-370. doi: 10.1007/s11523-018-0564-3.
6
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.肿瘤学中激酶抑制剂治疗药物监测的实用建议
Clin Pharmacol Ther. 2017 Nov;102(5):765-776. doi: 10.1002/cpt.787. Epub 2017 Sep 7.
7
Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.基于皮升液滴数字PCR检测晚期BRAF突变黑色素瘤患者循环肿瘤DNA及维莫非尼血药浓度
Target Oncol. 2017 Jun;12(3):365-371. doi: 10.1007/s11523-017-0491-8.